Loading
companiesCompany
Orum Therapeutics
Orum Therapeutics attaches protein-destroying drugs to antibodies so they are delivered only into cancer cells. Its lead medicine for acute myeloid leukaemia is entering human trials, and the company is listed on the Korean stock market.
Overview
Orum Therapeutics (Daejeon, South Korea, with US operations in Boston) pioneered degrader-antibody conjugates (DACs) through its Dual-Precision Targeted Protein Degradation (TPD²) approach, in which antibodies deliver catalytic protein degrader payloads selectively to cancer cells to improve efficacy, safety and half-life relative to systemic degraders. ORM-5029, a HER2-directed GSPT1 degrader conjugate, entered a phase 1 trial in HER2-expressing solid tumours in November 2022. ORM-6151, a CD33-directed GSPT1 degrader for acute myeloid leukaemia and high-risk MDS, was acquired by Bristol Myers Squibb in November 2023 after FDA phase 1 clearance. The current lead, ORM-1153, a CD123-GSPT1 DAC for AML, received FDA IND clearance in August 2026. The company raised a USD 84 million Series B in 2021, listed on KOSDAQ in February 2025 (KRX: 475830) and secured about USD 100 million in convertible preferred stock in December 2025.
Headquarters
Daejeon, KR
Funding
All startupsPublic
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · KOSDAQ listing, 2,500,000 shares at KRW 20,000, gross proceeds about KRW 50 billion; trading from 14 February 2025 under code 475830 | 2025 | undisclosed | orumrx.com |
| Series C · Post-IPO convertible preferred stock investment of KRW 145 billion (approximately USD 100 million) led by KB Investment; the company does not use a series letter | 2025 | $100M | orumrx.com |
| Series B · Includes a previously announced USD 30 million tranche; led by IMM Investment | 2021 | $84M | orumrx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · 475830.KQ
Stage
Public
Website
Notes
top- The December 2025 convertible preferred round is labelled Series C here for schema purposes only.
Similar pages
- CompanyCullgen
Shares Degrader-antibody conjugate (DAC), PROTACs & molecular glues (targeted protein degradation).
- CompanyPrelude Therapeutics
Shares Degrader-antibody conjugate (DAC), PROTACs & molecular glues (targeted protein degradation).
- TreatmentPivekimab sunirine
Shares CD123, Acute myeloid leukaemia, Antibody-drug conjugate (ADC).
- CompanyVor Biopharma
Shares CD33, Acute myeloid leukaemia.
- TreatmentTagraxofusp
Shares CD123, Acute myeloid leukaemia.
- TrialALFA-0701
Shares CD33, Acute myeloid leukaemia, Antibody-drug conjugate (ADC).
- TechnologyAntibody-oligonucleotide conjugates
Shares Degrader-antibody conjugate (DAC), Antibody-drug conjugate (ADC).
- IdeaUse antibodies to deliver protein-destroying drugs into the right cells
Shares Degrader-antibody conjugate (DAC), PROTACs & molecular glues (targeted protein degradation), Antibody-drug conjugate (ADC).